Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-mi-2 autoantibodies

Rheumatology (United Kingdom)

Volumn 51, Issue 8, 2012, Pages 1508-1513

  Muro, Yoshinao ^a   Ishikawa, Asuka ^a   Sugiura, Kazumitsu ^a   Akiyama, Masashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibodies; Dermatomyositis; Mi 2; TIF1 ; TIF1

Indexed keywords

AUTOANTIBODY; MI 2 ANTIBODY; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PAPULE; PRIORITY JOURNAL; RASH; SEROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOANTIGENS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOPRECIPITATION; INFANT; MALE; MIDDLE AGED; NUCLEAR PROTEINS; RECOMBINANT PROTEINS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84865192477     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes073     Document Type: Article

References (21)

1. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010;1184:134-53.
2. Hoshino K, Muro Y, Sugiura K et al. Anti-MDA5 and anti-TIF1-g antibodies have clinical significance for patients with dermatomyositis. Rheumatology 2010;49: 1726-33.
3. Kaji K, Fujimoto M, Hasegawa M et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 2007;46:25-8.
4. Trallero-Araguás E, Rodrigo-Pendás JA, Selva- O'Callaghan A et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012;64:523-32.
5. Fujimoto M, Hamaguchi Y, Kaji K et al. Myositis-specific anti-155/140 autoantibodies target transcriptional intermediary factor 1 family proteins. Arthritis Rheum 2012;64: 513-22.
6. Targoff IN, Mamyrova G, Trieu EP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006;54:3682-9.
7. Targoff IN. Serological findings. In: Kagen LJ, ed. The inflammatory myopathies. Dordrecht: Humana Press/ Springer, 2009:165-90.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
10. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002;46: 626-36.
11. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-86.
12. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007;66:1345-9.
13. Watanabe A, Kodera M, Sugiura K et al. Anti-DFS70 antibodies in 597 healthy workers. Arthritis Rheum 2004; 50:892-900.
14. Ishikawa A, Muro Y, Sugiura K, Akiyama M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology 2012;51:1181-7.
15. Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/ interstitial lung disease during disease remission. Rheumatology 2012;51:800-4.
16. Shimono Y, Murakami H, Kawai K et al. Mi-2 beta associates with BRG1 and RET finger protein at the distinct regions with transcriptional activating and repressing abilities. J Biol Chem 2003;278:51638-45.
17. Moser JJ, Chan EK, Fritzler MJ. Optimization of immunoprecipitation-western blot analysis in detecting GW182-associated components of GW/P bodies. Nat Protoc 2009;4:674-85.
18. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 2009;48:607-12.
19. Nilasena DS, Trieu EP, Targoff IN. Analysis of the Mi-2 autoantigen of dermatomyositis. Arthritis Rheum 1995;38: 123-8.
20. Ramírez J, Hagman J. The Mi-2/NuRD complex: a critical epigenetic regulator of hematopoietic development, differentiation and cancer. Epigenetics 2009;4: 532-6.
21. Schultz DC, Friedman JR, Rauscher FJ 3rd. Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD. Genes Dev 2001;15: 428-43.